GTXI GTx Inc.

GTx, Inc. to Report Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017

MEMPHIS, Tenn.--(BUSINESS WIRE)--

GTx, Inc. (NASDAQ: GTXI) today announced that the timing for its fourth quarter and full year 2016 financial results press release will be Wednesday, March 15, 2017, prior to the opening of the U.S. stock markets. The Company is not planning to host a conference call or webcast on that date, but will continue to provide periodic updates on clinical trial results and other material company developments as appropriate throughout the remainder of the year.

About GTx

GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions.

EN
07/03/2017

Underlying

GTXIGTx Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GTx Inc.

 PRESS RELEASE
Free
GTXI GTX INC.

GTx to Present Phase 2 Enobosarm Clinical Trial Results in Stress Urin...

MEMPHIS, Tenn.--(BUSINESS WIRE)-- GTx, Inc. (Nasdaq: GTXI) today announced an upcoming podium presentation highlighting the clinical results from the Company’s open-label, Phase 2 proof-of-concept clinical trial evaluating enobosarm 3 mg in postmenopausal women with stress urinary incontinence (SUI). The Company plans to summarize previously presented results, plus present additional data demonstrating duration of response following completion of treatment from women who have now reached seven months post-treatment. The presentation w...

April 16, 2018 1 EN
 PRESS RELEASE
Free
GTXI GTX INC.

GTx Announces Early Completion of Patient Enrollment in the ASTRID Tri...

MEMPHIS, Tenn.--(BUSINESS WIRE)-- GTx, Inc. (Nasdaq: GTXI) today announced that it has completed patient enrollment several months ahead of schedule in its placebo-controlled, Phase 2 clinical trial of enobosarm in postmenopausal women with stress urinary incontinence (SUI). The ASTRID (Assessing Enobosarm for Stress Urinary Incontinence Disorder) trial enrolled 493 women at over 60 clinical trial centers across the United States. Top-line results are expected early in the fourth quarter this year. "Due to overwhelming intere...

April 9, 2018 1 EN
 PRESS RELEASE
Free
GTXI GTX INC.

GTx Provides Corporate Update and Reports Fourth Quarter and Full Year...

MEMPHIS, Tenn.--(BUSINESS WIRE)-- GTx, Inc. (Nasdaq:GTXI) today reported financial results for the fourth quarter and year ended December 31, 2017 and highlighted recent accomplishments and upcoming milestones. “2017 was a transformational year for GTx, marked by positive results from our Phase 2 proof-of-concept clinical trial in post-menopausal women with stress urinary incontinence and the initiation of the ASTRID trial, a Phase 2 placebo-controlled clinical trial of enobosarm for the treatment of SUI,” said Robert J. Will...

March 12, 2018 1 EN
 PRESS RELEASE
Free
GTXI GTX INC.

GTx Announced New Data Demonstrating Enobosarm’s Potential to Treat ...

MEMPHIS, Tenn.--(BUSINESS WIRE)-- GTx, Inc. (Nasdaq:GTXI) today announced additional results from a Phase 2 proof-of-concept clinical trial of 3 mg enobosarm administered orally in postmenopausal women with stress urinary incontinence (SUI), including magnetic resonance imaging (MRI) results from patients’ pelvic floor muscle. New data in a subset of women also suggests a positive treatment effect of enobosarm for urge incontinence (UI) suggesting a possible treatment effect for women with mixed incontinence. Results from a pre-specif...

March 5, 2018 1 EN
 PRESS RELEASE
Free
GTXI GTX INC.

GTx Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Inconti...

MEMPHIS, Tenn.--(BUSINESS WIRE)-- GTx, Inc. (Nasdaq: GTXI) today announced the acceptance of an abstract on clinical results from an ongoing, open-label, Phase 2 proof-of-concept clinical trial evaluating enobosarm 3 mg in postmenopausal women with stress urinary incontinence (SUI). This study is the first clinical trial evaluating an orally-administered selective androgen receptor modulator (SARM) for SUI. The clinical results will be outlined during a podium presentation at the Society of Urodynamics, Female Pelvic Medicine...

February 22, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch